Evidence map›Paper›PMID 38732267›Full record

ArticleInternational journal of molecular sciences2024

Natural Compounds for Bone Remodeling: A Computational and Experimental Approach Targeting Bone Metabolism-Related Proteins.

Alexandros-Timotheos Loukas, Michail Papadourakis, Vasilis Panagiotopoulos, Apostolia Zarmpala, Eleni Chontzopoulou, Stephanos Christodoulou, Theodora Katsila, Panagiotis Zoumpoulakis, Minos-Timotheos Matsoukas

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Molecular-level understanding of the aging bone and regeneration mechanisms using computational methods.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexandros-Timotheos LoukasDepartment of Food Science and Technology, University of West Attica, Ag. Spyridonos, 12243 Egaleo, Greece.
Michail PapadourakisCloudpharm Private Company, Kifissias Avenue 44, 15125 Marousi, Greece.ORCID 0000-0002-9969-5871
Vasilis PanagiotopoulosCloudpharm Private Company, Kifissias Avenue 44, 15125 Marousi, Greece.ORCID 0000-0003-1563-2302
Apostolia ZarmpalaCloudpharm Private Company, Kifissias Avenue 44, 15125 Marousi, Greece.
Eleni ChontzopoulouCloudpharm Private Company, Kifissias Avenue 44, 15125 Marousi, Greece.
Stephanos ChristodoulouCloudpharm Private Company, Kifissias Avenue 44, 15125 Marousi, Greece.
Theodora KatsilaInstitute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.ORCID 0000-0002-6263-4231
Panagiotis ZoumpoulakisDepartment of Food Science and Technology, University of West Attica, Ag. Spyridonos, 12243 Egaleo, Greece.
Minos-Timotheos MatsoukasCloudpharm Private Company, Kifissias Avenue 44, 15125 Marousi, Greece.

Funding

European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE T2EDK-03847
6 · The paper itself

Abstract

Osteoporosis, characterized by reduced bone density and increased fracture risk, affects over 200 million people worldwide, predominantly older adults and postmenopausal women. The disruption of the balance between bone-forming osteoblasts and bone-resorbing osteoclasts underlies osteoporosis pathophysiology. Standard treatment includes lifestyle modifications, calcium and vitamin D supplementation and specific drugs that either inhibit osteoclasts or stimulate osteoblasts. However, these treatments have limitations, including side effects and compliance issues. Natural products have emerged as potential osteoporosis therapeutics, but their mechanisms of action remain poorly understood. In this study, we investigate the efficacy of natural compounds in modulating molecular targets relevant to osteoporosis, focusing on the Mitogen-Activated Protein Kinase (MAPK) pathway and the gut microbiome's influence on bone homeostasis. Using an in silico and in vitro methodology, we have identified quercetin as a promising candidate in modulating MAPK activity, offering a potential therapeutic perspective for osteoporosis treatment.

Indexed as

Biological ProductsBone RemodelingOsteoporosisAnimalsBone and BonesGastrointestinal MicrobiomeHumansMAP Kinase Signaling SystemOsteoblastsOsteoclastsQuercetinBiological ProductsQuercetinbone metabolismMAPKsmolecular dockingmolecular dynamics simulationsnatural compoundsosteoporosisquercetin

Identifiers

PMID38732267
PMCPMC11084538

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.